References
- Rennard SI. COPD: overview of definitions, epidemiology and factors influencing its development. Chest 1998;113(4 Suppl): 235-241S
- American Lung Association, Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality, February 2010. Available at: http://www.lungusa.org/finding-cures/our-research/epidemiology-and-statistics-rpts.html <http://www.lungusa.org/finding-cures/our-research/epidemiology-and-statistics-rpts.html.> Accessed July 26, 2010
- Miller JD, Foster T, Boulanger L, et al. Direct cost of COPD in the U.S.: an analysis of medical expenditure panel survey (MEPS) data. COPD 2005;3:311-318
- Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: Results of the confronting COPD survey. Respir Med 2003;97(Suppl C):S81-89
- Cannon HE. Assessing the need for a clinical COPD care program in a managed care organization. J Manag Care Pharm 2004;10(4 Suppl):S17-21
- Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-2658
- Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285
- Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276
- GOLD - the Global Initiative for Chronic Obstructive Lung Disease. Available at: http://www.goldcopd.com/ <http://www.goldcopd.com/> Accessed August 2009
- Sin DD, McAlister FA, Man P, et al. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003;290:2301-2312
- Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125:249-259
- Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yea treatment with tiotropium. Eur Respir J 2002;19:209-216
- Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. <http://www.ncbi.nlm.nih.gov/pubmed/10208192?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=43> Chest 1999;115:957-965
- Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-943
- Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456
- Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004;22:741-749
- Akazawa M, Hayflinger C, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-448
- Delea TE, Hagiwara M, Dalal AA, et al. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin 2009;25:1-13
- Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan® Databases. Thomson Reuters. July 2009. Web site http://thomsonreuters.com/products_services/healthcare/healthcare_products/pharmaceuticals/epidemiolgy_res/mktscan_res_db Accessed January 16, 2010
- The Kaiser Family Foundation, Examining Sources of Coverage Among Medicare Beneficiaries: Supplemental Insurance, Medicare Advantage, and Prescription Drug Coverage Findings from the Medicare Current Beneficiary Survey, 2006. Available at: http://www.kff.org/medicare/upload/7801.pdf <http://www.kff.org/medicare/upload/7801.pdf> Accessed July 26, 2010
- Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the “Top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14
- Crown WH, Finkelstein S, Berndt FR, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychol 2002;63:963-971
- Durden E, Ben Joseph R, Huse D, et al. The economic costs of obesity to self-insured employers. J Occup Environ Med 2008;50:991-997
- Schulman K, Kehles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-2342
- US Department of Labor Bureau of Labor Statistics Consumer Price Index. Available at: http://www.bls.gov/cpi/cpifact4.htm Accessed August 2009
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1997;40:373-383
- D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol 1996;49:1429-1433
- Nelder JA, Wedderburn R. Generalized linear models. J R Stat Soc, Ser A (General) 1972;135:370-384
- Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63:962-967
- Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555